Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Oncology Companion Diagnostic market. The report considers 2018-2020 historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.
Oncology Companion Diagnostic market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
The Oncology Companion Diagnostic market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the Oncology Companion Diagnostic products across developed and developing countries of the world.
Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of Oncology Companion Diagnostic products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Oncology Companion Diagnostic market.
To learn more about this report
Increasing research and development spending on Oncology Companion Diagnostic development has been the leading industry trend of Oncology Companion Diagnostic market
The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be wit-nessed from the increasing spending on research and development and growing number of new product approvals.
To learn more about this report
| Report Attributes | Details |
| The market size value in 2021 | USD XX.XX Million |
| CAGR (2021 - 2028) | XX.XX % |
| The Revenue forecast in 2028 | USD XX.XX Million |
| Base year for estimation | 2021 |
| Historical data | 2018-2019 |
| Forecast period | 2022-2028 |
| Quantitative units |
|
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered | By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook | Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohistochemistry (IHC), In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH), Others |
| By Application Outlook | Hospital, Pathology/Diagnostic Laboratory, Academic Medical Center, Other |
| Regional scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope | U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled | Agilent Technologies, Inc., Illumina, Inc., Qiagen N.V., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., ARUP Laboratories, Abbott, Myriad Genetics, Inc., bioMérieux SA, Invivoscribe, Inc. |
| Customization Available | Yes, the report can be tailored to meet your specific requirements. |
1 Methodology and Scope
1.1 Market segmentation & scope
1.2 Information Procurement
1.2.1 Purchased Database
1.2.2 Eternity’s Internal Database
1.2.3 Secondary sources & third-party perspectives
1.2.4 Primary Research
1.3 Information analysis
1.4 Market formulation & data visualization
1.5 Data validation & publishing
2 Executive Summary
3 Oncology Companion Diagnostic Market Variables, Trends & Scope
3.1 Market Dynamics
3.1.1 Market Driver Analysis
3.1.2 Market Restraints
3.1.3 Market Challenge Analysis
3.1.4 Market Opportunities
3.1.5 Micro & Macro Indicator
3.2 Impact of COVID-19 Pandemic on Global Oncology Companion Diagnostic Market
3.2.1 Overview of Changing Landscape
3.2.2 Pre-covid & Post-Covid Market Analysis
3.3 Market Attractiveness Analysis
3.4 Regulatory Scenario
3.5 Industry Trend Analysis- Historic and Future Trend Assessment
3.6 Merger & Acquisition
3.7 New System Launch/Approvals
3.8 Market Analysis Tools
3.8.1 Porter’s Five Forces
3.8.2 PEST Analysis
3.8.3 Value Chain Analysis
3.9 Key Company Ranking Analysis, 2020
4 Global Oncology Companion Diagnostic Market Analysis and Forecast, By Type
4.1 Overview & Definition
4.2 Key Trends
4.3 Global Oncology Companion Diagnostic Market Value (US$ Mn) Forecast, by Type (2019 – 2028)
4.2.1 Polymerase Chain Reaction (PCR)
4.2.2 Next-Generation Sequencing (NGS)
4.2.3 Immunohistochemistry (IHC)
4.2.4 In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
4.2.5 Others
4.4 Type Comparison Matrix
4.5 Global Oncology Companion Diagnostic Market Attractiveness, By Type
5 Global Oncology Companion Diagnostic Market Analysis and Forecast, By Application
5.1 Overview & Definition
5.2 Key Trends
5.3 Global Oncology Companion Diagnostic Market Value (US$ Mn) Forecast, by Application (2019 – 2028)
5.3.1 Hospital
5.3.2 Pathology/Diagnostic Laboratory
5.3.3 Academic Medical Center
5.3.4 Other
5.4 Application Comparison Matrix
5.5 Global Oncology Companion Diagnostic Market Attractiveness, by Application
6 Global Oncology Companion Diagnostic Market Analysis and Forecast, By Region
6.1 Overview & Definition
6.2 Key Trends
6.3 Global Oncology Companion Diagnostic Market Value (US$ Mn) Forecast, by Region (2019 – 2028)
6.4 North America
6.5 Europe
6.6 Asia Pacific
6.7 Latin America
6.8 Middle East & Africa
7 Global Oncology Companion Diagnostic Market Attractiveness, by Region
8 North America Oncology Companion Diagnostic Market Analysis and Forecast
8.1 Key Findings
8.2 North America Oncology Companion Diagnostic Market Analysis (US$ Mn) and Forecast, By Type (2019-2028)
8.2.1 Polymerase Chain Reaction (PCR)
8.2.2 Next-Generation Sequencing (NGS)
8.2.3 Immunohistochemistry (IHC)
8.2.4 In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
8.2.5 Others
8.3 North America Oncology Companion Diagnostic Market Analysis (US$ Mn) and Forecast, By Application (2019-2028)
8.3.1 Hospital
8.3.2 Pathology/Diagnostic Laboratory
8.3.3 Academic Medical Center
8.3.4 Other
8.4 North America Oncology Companion Diagnostic Market Analysis (US$ Mn) and Forecast, By Country (2019-2028)
8.4.1 U.S.
8.4.2 Canada
8.4.3 Rest of North America
8.5 North America Oncology Companion Diagnostic Market Attractiveness Analysis
8.5.1 By Type
8.5.2 By Application
8.5.3 By Country
9 Europe Oncology Companion Diagnostic Market Analysis and Forecast
9.1 Key Findings
9.2 Europe Oncology Companion Diagnostic Market Analysis (US$ Mn) and Forecast, By Type (2019-2028)
9.2.1 Polymerase Chain Reaction (PCR)
9.2.2 Next-Generation Sequencing (NGS)
9.2.3 Immunohistochemistry (IHC)
9.2.4 In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
9.2.5 Others
9.3 Europe Oncology Companion Diagnostic Market Analysis (US$ Mn) and Forecast, By Application (2019-2028)
9.3.1 Hospital
9.3.2 Pathology/Diagnostic Laboratory
9.3.3 Academic Medical Center
9.3.4 Other
9.4 Europe Oncology Companion Diagnostic Market Analysis (US$ Mn) and Forecast, By Country (2019-2028)
9.4.1 U.K.
9.4.2 Germany
9.4.3 France
9.4.4 Italy
9.4.5 Rest of Europe
9.5 Europe Oncology Companion Diagnostic Market Attractiveness Analysis
9.5.1 By Type
9.5.2 By Application
9.5.3 By Country
10 Asia Pacific Oncology Companion Diagnostic Market Analysis and Forecast
10.1 Key Findings
10.2 Asia Pacific Oncology Companion Diagnostic Market Analysis (US$ Mn) and Forecast, By Type (2019-2028)
10.2.1 Polymerase Chain Reaction (PCR)
10.2.2 Next-Generation Sequencing (NGS)
10.2.3 Immunohistochemistry (IHC)
10.2.4 In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
10.2.5 Others
10.3 Asia Pacific Oncology Companion Diagnostic Market Analysis (US$ Mn) and Forecast, By Application (2019-2028)
10.3.1 Hospital
10.3.2 Pathology/Diagnostic Laboratory
10.3.3 Academic Medical Center
10.3.4 Other
10.4 Asia Pacific Oncology Companion Diagnostic Market Analysis (US$ Mn) and Forecast, By Country (2019-2028)
10.4.1 China
10.4.2 India
10.4.3 Japan
10.4.4 South Korea
10.4.5 Rest of APAC
10.5 Asia Pacific Oncology Companion Diagnostic Market Attractiveness Analysis
10.5.1 By Type
10.5.2 By Application
10.5.3 By Country
11 Latin America Oncology Companion Diagnostic Market Analysis and Forecast
11.1 Key Findings
11.2 Latin America Oncology Companion Diagnostic Market Analysis (US$ Mn) and Forecast, By Type (2019-2028)
11.2.1 Polymerase Chain Reaction (PCR)
11.2.2 Next-Generation Sequencing (NGS)
11.2.3 Immunohistochemistry (IHC)
11.2.4 In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
11.2.5 Others
11.3 Latin America Oncology Companion Diagnostic Market Analysis (US$ Mn) and Forecast, By Application (2019-2028)
11.3.1 Hospital
11.3.2 Pathology/Diagnostic Laboratory
11.3.3 Academic Medical Center
11.3.4 Other
11.4 Latin America Oncology Companion Diagnostic Market Analysis (US$ Mn) and Forecast, By Country (2019-2028)
11.4.1 Brazil
11.4.2 Rest of Latin America China
11.5 Latin America Oncology Companion Diagnostic Market Attractiveness Analysis
11.5.1 By Type
11.5.2 By Application
11.5.3 By Country
12 Middle East & Africa (MEA) Oncology Companion Diagnostic Market Analysis and Forecast
12.1 Key Findings
12.2 Middle East & Africa (MEA) Oncology Companion Diagnostic Market Analysis (US$ Mn) and Forecast, By Product Type (2019-2028)
12.2.1 Polymerase Chain Reaction (PCR)
12.2.2 Next-Generation Sequencing (NGS)
12.2.3 Immunohistochemistry (IHC)
12.2.4 In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
12.2.5 Others
12.3 Middle East & Africa (MEA) Oncology Companion Diagnostic Market Analysis (US$ Mn) and Forecast, By Application (2019-2028)
12.3.1 Hospital
12.3.2 Pathology/Diagnostic Laboratory
12.3.3 Academic Medical Center
12.3.4 Other
12.4 Middle East & Africa (MEA) Oncology Companion Diagnostic Market Analysis (US$ Mn) and Forecast, By Country (2019-2028)
12.4.1 GCC Countries
12.4.2 South Africa
12.4.3 Rest of MEA
12.5 Middle East & Africa (MEA) Oncology Companion Diagnostic Market Attractiveness Analysis
12.5.1 By Type
12.5.2 By Application
12.5.3 By Country
13 Competitive Landscape
13.1 Market Players – Competition Matrix
13.2 Market Share Analysis by Key Players, 2020 (%)
13.3 Company Profiles
13.3.1 Agilent Technologies
13.3.1.1 Company Overview
13.3.1.2 Company Snapshot
13.3.1.3 Financial Overview
13.3.1.4 Product Portfolio
13.3.1.5 Key Developments/Strategies
13.3.2 Inc.
13.3.3 Illumina
13.3.4 Inc.
13.3.5 Qiagen N.V.
13.3.6 Thermo Fisher Scientific Inc.
13.3.7 F. Hoffmann-La Roche Ltd.
13.3.8 ARUP Laboratories
13.3.9 Abbott
13.3.10 Myriad Genetics
13.3.11 Inc.
13.3.12 bioMérieux SA
13.3.13 Invivoscribe
13.3.14 Inc.
14 Key Takeaways
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
A faster and efficient way to cater to the needs with continuous iteration
Focus on Data Accuracy & Reliability
75+ Clients in Fortune 500
All your transactions are secured end-to-end, ensuring a satisfactory purchase
Ensure the best and affordable pricing
